Merck & Co Inc
MRKHealthcare|Drug Manufacturers - General|USA
$120.85
+0.00 (+0.00%)
DCF (FCF)
$75.40
Tangible Book
$1.76
Graham Number
$18.83
Earnings Power
$41.17
About
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Stock Price
+39.9%(1Y)
Pipeline Summary
731 total trials228
Phase 1
262
Phase 2
138
Phase 3
63
Phase 4
Terminated: 115Completed: 480NO_LONGER_AVAILABLE: 2Unknown: 33Withdrawn: 13Active: 46Recruiting: 35NOT_YET_RECRUITING: 6ENROLLING_BY_INVITATION: 1
Active Trials (81)
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
NCT04945460Hypertension, Pulmonary
Phase 2Active
Enrollment: 164 participants
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
NCT04143724Beta-Thalassemia
Phase 2Recruiting
Enrollment: 99 participants
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
NCT03634540Renal Cell Carcinoma (RCC)
Phase 2Active
Enrollment: 118 participants
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
NCT03401788VHL - Von Hippel-Lindau Syndrome
Phase 2Active
Enrollment: 50 participants
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
NCT04184050Multiple Myeloma in Relapse
Phase 1Active
Enrollment: 100 participants
BioScore
6.1/10
Watchlist
Ownership
Recent Insider Trades
Guindo ChirfiSELL
2026-02-1210,000 shares @ $121.46
Li Dean YSELL
2026-02-1010,235 shares @ $117.52
Zachary JenniferSELL
2026-02-09121,573 shares @ $119.15
Guindo ChirfiSELL
2026-02-0910,000 shares @ $118.41
Oosthuizen Johannes JacobusSELL
2026-02-0615,000 shares @ $121.87
Recent News
2026-04-06 19:00:27
2026-04-03 12:38:12
2026-04-02 12:25:56
2026-04-02 11:52:21
2026-04-02 11:52:01
Data last updated: Apr 7, 2026, 01:26 PM